Low-Dose Radiation Therapy to Lungs in Moderate COVID-19 Pneumonitis: A Case-Control Pilot Study (LOCORAD)
COVID-19, Pneumonia
About this trial
This is an interventional treatment trial for COVID-19 focused on measuring COVID-19, Pneumonia, Low dose radiotherapy, Cytokine storm
Eligibility Criteria
Inclusion Criteria:
- Reverse transcription polymerase chain reaction (RT-PCR) / Rapid Ag test positive
- Signed informed consent
- Age ≥ 50 yrs
- Respiratory rate : 25 - 30/min, breathless AND/OR
- Oxygen saturation by pulse oximetry (SpO2) in 90 - 93% on room air (readings taken after 5 mins of stopping oxygen supplementation)
- Rising levels of quantitative-CRP and/or D-Dimer and/or Ferritin in 2 consecutive samples taken 24 hours apart
Exclusion Criteria:
- Patient who have received vaccination for COVID-19 (single / both doses of any approved vaccine)
- Hemodynamic instability in shock and/or systolic BP < 90mm Hg
- Septicemia
- Disseminated intravascular coagulation
- Requiring ventilation
- Unable to lie down supine
- Severe acute respiratory distress with Fraction of inspired oxygen (FiO2) < 100mm Hg
- Cardiac defibrillator/pacemaker in situ
- Lymphocyte count < 1 x 106/ml
- Pregnancy and/or lactating mothers
- HIV and/or HbsAg positive patients
Sites / Locations
- Mahatma Gandhi Institute of Medical Sciences,Recruiting
- Mahatma Gandhi Institute of Medical SciencesRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
No Intervention
Study arm
Control Arm
10 patients of confirmed diagnosis of moderate COVID-19 who fulfil the inclusion criteria and give written informed consent would be in study arm. All patients, belong to both study and control groups would receive the same treatment (oxygen support, steroids, anticoagulant therapy, remdesivir and other supportive therapy) as per the Institute guidelines for management of moderate COVID-19 disease. Only low dose radiotherapy would be added to patients in the study arm.
10 patients of confirmed diagnosis of moderate COVID-19 who fulfil the inclusion criteria and have not given written informed consent would be in study arm. These patients would receive the same treatment (oxygen support, steroids, anticoagulant therapy, remdesivir and other supportive therapy) as per the Institute guidelines for management of moderate COVID-19 disease except low dose radiotherapy.